Hyderabad: Pharmaceutical company Biological E is expected to launch its Covid-19 vaccine ‘Corbevax’ by September end in the country. According to news agency ANI, the vaccine maker is expected to apply for an Emergency use License (EUL) by August end and will be supplying 300 million doses to the Government of India by December 2021.
The report claimed that the government has already booked Biological E’s COVID-19 vaccine Corbevax which is currently in advance phase 3 clinical trials for ‘at-risk manufacturing’ of the COVID-19 vaccine.
Union Minister of State for Health, Dr Bharati Pravin Pawar recentky said that the Government of India has also provided financial assistance to domestic vaccine manufacturer.
Earlier, it was reported that Biological-E’s RBD protein sub-unit vaccine Corbevax could be the most affordable vaccine in India once it gets emergency use approval. As per a report, two doses of Corbevax may even be priced below Rs 400, which is quite less as compared to the other Covid vaccines.
Last month, the Union Health Ministry had finalised arrangements with Hyderabad-based vaccine manufacturer to reserve 30 crore of Covid-19 vaccine doses.
The proposal of M/s Biological-E was examined and recommended for approval after due diligence by National Expert Group on Vaccine Administration for COVID-19 (NEGVAC).
“Biological-E COVID Vaccine candidate has been supported by Government of India from Preclinical stage to Phase-3 studies. Department of Biotechnology has not only provided financial assistance in terms of grant-in-aid of over Rs 100 cr but has also partnered with Biological-E to conduct all animal challenge and assay studies through its Research Institute Translational Health Science Technology Institute (THSTI), Faridabad,” the Union Health Ministry said in a release issued on June 3.
The Union Health Ministry further said the mission aims to bring to the citizens a safe, efficacious, affordable and accessible Covid-19 Vaccine.
Check out below Health Tools-
Calculate Your Body Mass Index ( BMI )